Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587249 · ClinicalTrials.gov registry record · Phase 1
ICC-1132 - Candidate Vaccine Against P Falciparum Malaria
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00587249 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 75 participants.
The verdict
NCT00587249, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purposes of this study are to evaluate the safety and immune responses (the body's defense system) to an investigational malaria vaccine called ICC-1132. Three different doses of the vaccine will be studied in 3 groups of people, and the results will be compared. The study will involve about 80 healthy volunteers, 18-45 years of age, who will receive an injection of a specific dose of the vaccine in their arm on 2 or 3 different days. Blood samples will be collected approximately 15 times for laboratory studies. Volunteers will record their temperature twice per day. Volunteers will complete a daily symptom diary for 7 days after each vaccination. Volunteers will participate in the study for up to 13 months.
Interventions
- BIOLOGICAL Malaria ICC-1132
- BIOLOGICAL Alhydrogel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587249
The ClinicalTrials.gov registry entry for NCT00587249 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Malaria ICC-1132 is the first listed.
NCT00587249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587249 about?
NCT00587249 is a clinical study titled "ICC-1132 - Candidate Vaccine Against P Falciparum Malaria". The purposes of this study are to evaluate the safety and immune responses (the body's defense system) to an investigational malaria vaccine called ICC-1132. Three different doses of the vaccine will be studied in 3 groups of people, and the results will be compared. The study will involve about 80 ...
What is the current status of trial NCT00587249?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2002-07. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00587249?
The interventions under investigation include: Malaria ICC-1132 (BIOLOGICAL), Alhydrogel (BIOLOGICAL).
Who is sponsoring clinical trial NCT00587249?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.